4-1BB CTL adoptive T cell therapy (Eutilex)

N/A

Report date: 2022/12/23 18:11:22

Base Information

Drug Name4-1BB CTL adoptive T cell therapy (Eutilex)

Drug Alias Name4-1BB CTL adoptive T cell therapy (cancer)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionCD8-positive T-Lymphocytes stimulantsT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEutilex

China Registration ClassN/A

Develop Information

Active CompaniesEutilex

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A